Charles River Laboratories | CRL - Interest Expense On Debt


Charles River Laboratories reported $30.34M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Agilent USD 25M 0 Mar/2026
Align Technology USD 6.93M 9.11M Mar/2026
Bio-Rad Laboratories USD 12.1M 200K Jun/2026
Bruker USD 17.8M 9.7M Jun/2026
Cardinal Health USD 79M 22M Jun/2026
Charles River Laboratories USD 30.34M 3.6M Jun/2026
Cigna USD 157.08B 3.82B Jun/2026
Concord Medical Services Hldg CNY 84.37M 32.34M Jun/2023
CVS Health USD 757M 17M Jun/2026
Danaher USD 107M 44M Jun/2026
Dentsply International USD 22M 2M Jun/2026
Elevance Health USD 364M 7M Jun/2026
Humana USD 197M 4M Jun/2026
Illumina USD 24M 2M Mar/2026
Incyte USD 582K 13K Jun/2026
Intrexon USD 2K 5K Jun/2024
IQVIA Holdings USD 197M 5M Jun/2026
Laboratory Of America USD 61.1M 6M Jun/2026
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Lonza CHF 84M 14M Jun/2025
McKesson USD 77M 18M Jun/2026
Merck EUR 137M 33M Jun/2026
Mettler Toledo International USD 17.25M 239K Jun/2026
Novartis USD 462M 119M Jun/2026
Pfizer USD 667M 4M Jun/2026
Quest Diagnostics USD 69M 2M Sep/2025
Revvity USD 22.99M 1.73M Jun/2026
Thermo Fisher Scientific USD 354M 11M Mar/2026
United Therapeutics USD 2.9M 200K Jun/2026
UnitedHealth USD 962M 7M Jun/2026
Veradigm USD 1.25M 641K Sep/2022
Waters USD 55M 13M Jun/2026
West Pharmaceutical Services USD 1.9M 1.7M Mar/2026